Log inSign up
Image
user avatar
Alnylam Pharmaceuticals
@Alnylam
Leader in #RNAiTherapeutics, having pioneered this innovative approach to silencing the genes that cause disease. Community guidelines: bit.ly/2FcRhJy.
Cambridge, MA
alnylam.com
Joined August 2009
619
Following
17.3K
Followers
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Apr 7, 2020
    To our patients and their caregivers, we want to assure you that we are here to support you during these difficult times caused by #COVID19. People living in the U.S. can contact Alnylam Assist for personalized support in accessing our medicines, if prescribed by their doctor.
    Image
    Learn more about the Alnylam Assist patient support program
    From alnylamassist.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Apr 15, 2020
    We know that due to #COVID19, patients & caregivers face unfamiliar and challenging circumstances. Alnylam Assist Case Managers are available to help those living in the U.S. prescribed our medicines with a full range of services including assistance with changes in site of care.
    Image
    Learn more and connect with Alnylam Assist
    From alnylamassist.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Aug 10, 2018
    We are thrilled to share the news that we have received @US_FDA approval for ONPATTRO (patisiran), our first commercial product and the first-ever #RNAi therapeutic.
    Image
    Alnylam Receives US FDA Approval for ONPATTRO (patisiran)
    From alnylam.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    May 23, 2019
    In a new LinkedIn #HardCases article, Dr. Bruce Wang of @ucsfhealth writes about the challenges faced by people living with acute hepatic #porphyria (AHP) in receiving an accurate diagnosis and his experiences as an AHP specialist. bit.ly/30GX13W
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Nov 14, 2019
    ICYMI, last week we announced that we have initiated ILLUMINATE-C, a global Phase 3 study of lumasiran, our investigational #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1), in patients with advanced renal disease, including patients on dialysis.
    Image
    Learn more about the Initiation of ILLUMINATE-C
    From alnylam.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    May 30, 2019
    LinkedIn #HardCases recently published a new article by Dr. Bruce Wang of @UCSFHospitals in which he writes about the challenges in receiving an accurate diagnosis faced by people living w/ acute hepatic #porphyria (AHP) & his experiences working w/ patients as an AHP specialist.
    Image
    LinkedIn Hard Cases - Acute Hepatic Porphyrias by Dr. Bruce Wang
    From bit.ly
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Dec 1, 2017
    Colin’s account of his “living nightmare” is all too familiar to people living with the debilitating pain and chronic symptoms of #porphyria #RareDisease bit.ly/2zzgB4v
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Nov 20, 2019
    We are pleased to announce that Alnylam Assist, our patient services program, can now provide patients in the U.S. prescribed GIVLAARI (givosiran) and their families with comprehensive support and guidance.
    Image
    Learn more about the Alnylam Assist patient support program
    From alnylamassist.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Aug 13, 2018
    We’re committed to making the therapies we develop available to those who may benefit from them. Alnylam Assist provides patients in the U.S. with a range of services from assistance with insurance coverage to financial support and guidance.
    Image
    Learn more and connect with Alnylam Assist
    From alnylamassist.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Sep 9, 2022
    Symptoms of #hATTR #amyloidosis can vary widely and resemble other conditions. If you’ve reached your tipping point where symptoms can no longer be overlooked, take the next steps - learn more about this #RareDisease and talk to your healthcare provider.
    Image
    00:00
    Learn more about hATTR amyloidosis at hattrbridge.com
    From attrrevealed.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Aug 22, 2022
    Despite three visits to the ER and undergoing countless tests, Amalia still had no answers to explain her recurring painful attacks. Learn how she found escape through her art as she navigated the challenging journey to receiving her diagnosis of acute hepatic #porphyria (AHP).
    Image
    Learn about Amalia’s AHP symptoms and diagnosis
    From amaliasstory.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Aug 13, 2018
    To all of the patients, family members, caregivers, advocates and healthcare professionals whose support and trust made this exciting news – the approval of ONPATTRO (patisiran) AND the 1st #RNAi therapeutic – possible, we say THANK YOU! #raredisease
    Image
    Read the Press Release
    From alnylam.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Nov 20, 2019
    We are thrilled to share the news that we have received @US_FDA approval for GIVLAARI (givosiran), the second #RNAi therapeutic from Alnylam approved by the FDA in less than 2 years. #raredisease #biotech
    Image
    Alnylam Receives U.S. FDA Approval for GIVLAARI (givosiran)
    From alnylam.com
  • user avatar
    Alnylam Pharmaceuticals
    @Alnylam
    Nov 16, 2018
    We're so proud to be named to the @BostonGlobe's #TopPlacestoWork 2018 list - our 4th yr in a row! Huge thanks to our >1000 passionate, patient-focused, "change the world" employees, who have said "#ChallengeAccepted" & are working to bring #RNAi therapeutics to patients in need.
    Image
    Boston Globe Top Places to Work 2018 - See the List
    From bostonglobe.com